

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



In re application of:

PRICE *et al.*

Appl. No. 09/390,634

Filed: September 7, 1999

For: **Method for Expanding Embryonic
Stem Cells in Serum-Free Culture
(As Amended)**

Art Unit: 1651

Examiner: To Be Assigned

Atty. Docket: 0942.4190002/RWE/GER

#20

Request for Corrected Official Filing Receipt

Assistant Commissioner for Patents
Washington, D.C. 20231

Attn: Application Processing Division
Customer Correction Branch

Sir:

Applicants hereby request that a corrected Official Filing Receipt be issued and sent to the undersigned representative. Specifically, the following corrections to the Official Filing Receipt are requested:


In the "TOT CL" section, please change "58" to --38--.

In the "Applicant(s)" section, please change "GLDSBOROUGH" to --GOLDSBOROUGH--.

In support of the above request, a photocopy of the instant Official Filing Receipt is enclosed with the corrections noted in red. It is requested that a corrected Official Filing Receipt be issued, and sent to the undersigned at the earliest possible time.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.


Grant E. Reed
Attorney for Applicants
Registration No. 41,264

Date: 12/21/99

1100 New York Avenue, N.W.
Suite 600
Washington, D.C. 20005-3934
(202) 371-2600

LING RECEIPT



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
ASSISTANT SECRETARY AND COMMISSIONER
OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTORNEY DOCKET NO.	DRWGS	TOT CL	IND CL
09/390,634	09/07/99	1651	\$2,796.00	0942.4190002	2	58	17

38

STERNE KESSLER GOLDSTEIN & FOX
1100 NEW YORK AVENUE N W
SUITE 600
WASHINGTON DC 20005-3934



Receipt is acknowledged of this nonprovisional Patent Application. It is considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the charges noted thereon. If you received a "Notice to File Missing Parts of Application" ("Missing Parts Notice") in this application, please submit any corrections to this Filing Receipt with your reply to the "Missing Parts Notice." When the PTO processes the reply to the "Missing Parts Notice," the PTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

GOLDSBOROUGH

Applicant(s) PAUL J. PRICE, GRAND ISLAND, NY; MINDY D. GOLDSBOROUGH,
GAITHERSBURG, MD; MARY LYNN TILKINS, NIAGARA FALLS, NY.

CONTINUING DATA AS CLAIMED BY APPLICANT-
THIS APPLN IS A DIV OF 08/781,772 01/10/97

IF REQUIRED, FOREIGN FILING LICENSE GRANTED 09/22/99
TITLE
EMBRYONIC STEM CELL SERUM REPLACEMENT

PRELIMINARY CLASS: 435

RECEIVED
OCT - 4 1999

STERNE, KESSLER, GOLDSTEIN & FOX PLLC

PP RWE 1015 RWD 10/5/99
GER 10/5/99

DATA ENTRY BY: RIVERS, ANNETTE

TEAM: 01 DATE: 09/22/99

|||||

(See reverse for new important information)

LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "FOREIGN FILING LICENSE GRANTED" followed by a date appears on the reverse side of this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.11. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related application(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations, especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR Parts 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "FOREIGN FILING LICENSE GRANTED" DOES NOT appear on the reverse side of this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

PLEASE NOTE ---- The Following Information about the Filing Receipt:

The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.

The words "new," "improved," "improvement," "improvements in or relating to" are not included as the first words in the title of an application because a patent application is, by nature, a new idea or improvement.

The title may be truncated if it consists of more than 4 lines of 70 characters each (letters and spaces combined).

The inventor information may be truncated if the family name consists of more than 25 characters (letters and spaces combined) and if the given name consists of more than 25 characters (letters and spaces combined). The inventor's residence allows for up to 40 characters (letters and spaces combined).

The docket number allows a maximum of 12 characters.

If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."

Customer Address may have been modified to conform to U.S. Postal rules.

Please direct correction, including a copy of your Filing Receipt, to:
Assistant Commissioner for Patents
Office of Initial Patent Examination
Customer Service Center
Washington, DC 20231

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

ATTORNEYS AT LAW

1100 NEW YORK AVENUE, N.W., SUITE 600

WASHINGTON, D.C. 20005-3934

(202) 371-2600

FACSIMILE: (202) 371-2540; (202) 371-6566

RECEIVED
DEC 22 1999

TECH CENTER 1600/2900

ROBERT GREENE STERNE
EDWARD J. KESSLER
JORGE A. GOLDSTEIN
SAMUEL L. FOX
DAVID K.S. CORNWELL
ROBERT W. ESMOND
TRACY-GENE G. DURKIN
MICHELE A. CIMBALA
MICHAEL B. RAY
ROBERT E. SOKOHL

ERIC K. STEFFE
MICHAEL O. LEE
STEVEN R. LUDWIG
JOHN M. COVERT*
LINDA E. ALCORN
RAZ E. FLESHNER
ROBERT C. MILLONIG
MICHAEL V. MESSINGER
JUDITH U. KIM
TIMOTHY J. SHEA, JR.


DONALD R. MCPHAIL
PATRICK E. GARRETT
STEPHEN G. WHITESIDE
JEFFREY T. HELVEY*
HEIDI L. KRAUS
JEFFREY R. KURIN
RAYMOND MILLIEN
PATRICK D. O'BRIEN
LAWRENCE B. BUGAISKY
CRYSTAL D. SAYLES*

EDWARD W. YEE
ALBERT L. FERRO*
DONALD R. BANOWIT*
PETER A. JACKMAN
MOLLY A. MCCALL
TERESA U. MEDLER
JEFFREY S. WEAVER
KRISTIN K. VIDOVICH
ANDREW S. ROBERTS*
KENDRICK P. PATTERSON*

DONALD J. FEATHERSTONE**
KAREN R. MARKOWICZ**
GRANT E. REED**
SUZANNE E. ZISKA**
BRIAN J. DEL BUONO**
VINCENT L. CAPUANO**
ANDREA J. KAMAGE**
NANCY J. DEGEN**

ROBERT H. BENSON*
OF COUNSEL

*BAR OTHER THAN D.C.
**REGISTERED PATENT AGENTS



December 21, 1999

WRITER'S DIRECT NUMBER:
(202) 789-5507

Assistant Commissioner for Patents
Washington, D.C. 20231

Re: U.S. Utility Patent Application
Appl. No. 09/390,634; Filed: September 7, 1999
For: **Method for Expanding Embryonic Stem Cells in Serum-Free Culture (As Amended)**
Inventors: Price *et al.*
Our Ref: 0942.4190002/RWE/GER

Sir:

Transmitted herewith for appropriate action are the following documents:

1. Second Preliminary Amendment;
2. Information Disclosure Statement;
3. A listing of the ninety-six (96) cited documents on Form PTO-1449 (24 sheets);
4. A copy of the following cited documents: AN2, AR1, AS8, AS11, AS19, AS22, AT22, AR23, AS23, AT23, and AR24; and
5. One (1) return postcard.


It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Assistant Commissioner for Patents
December 21, 1999
Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036. A duplicate copy of this letter is enclosed.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Grant E. Reed
Attorney for Applicants
Registration No. 41,264

Enclosures

419-2.1DS&2PRELIM.TRANS.WPD
SKGF Rev. 9/23/98 dcw

Due Date: None

Applicants: Price *et al.*

Art Unit: 1651

Examiner: To Be Assigned

Application No.: 09/390,634

Docket: 0942.4190002

Filed: September 7, 1999

Atty: RWE/GER

For: **Method for Expanding Embryonic Stem Cells in Serum-Free Culture
(As Amended)**

When receipt stamp is placed hereon, the USPTO acknowledges receipt of the following documents:

1. PTO Transmittal letter (*in duplicate*);
2. Second Preliminary Amendment;
3. Information Disclosure Statement;
4. A listing of the ninety-six (96) cited documents on Form PTO-1449 (24 sheets);
5. A copy of the following cited documents: AN2, AR1, AS8, AS11, AS19, AS22, AT22, AR23, AS23, AT23, and AR24; and
6. One (1) return postcard.

Please Date Stamp and Return To Our Courier



TECH CENTER 1600/2900

FEB 19 2002

RECEIVED

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

ATTORNEYS AT LAW

1100 NEW YORK AVENUE, N.W., SUITE 600

WASHINGTON, D.C. 20005-3934

(202) 371-2600

FACSIMILE: (202) 371-2540; (202) 371-6566

Receipt
FILE COPY
APR 07 2000

TECH CENTER 1600/2900

ROBERT GREENE STERNE
EDWARD J. KESSLER
JORGE A. GOLDSTEIN
SAMUEL L. FOX
DAVID K.S. CORNWELL
ROBERT W. ESMOND
TRACY-GENE G. DURKIN
MICHELE A. CIMBALA
MICHAEL B. RAY
ROBERT E. SOKOHL

ERIC K. STEFFE
MICHAEL O. LEE
STEVEN R. LUDWIG
JOHN M. COVERT*
LINDA E. ALCORN
RAZ E. FLESHNER
ROBERT C. MILLONIG
MICHAEL V. MESSINGER
JUDITH U. KIM
TIMOTHY J. SHEA, JR.

DONALD R. MCPHAIL
PATRICK E. GARRETT
STEPHEN G. WHITESIDE
JEFFREY T. HELVEY*
HEIDI L. KRAUS
JEFFREY R. KURIN
RAYMOND MILLIEN
PATRICK D. O'BRIEN
LAWRENCE B. BUGAISKY
CRYSTAL D. SAYLES*

EDWARD W. YEE
ALBERT L. FERRO*
DONALD R. BANOWIT*
PETER A. JACKMAN
MOLLY A. MCCALL
TERESA U. MEDLER
JEFFREY S. WEAVER
KRISTIN K. VIDOVICH
ANDREW S. ROBERTS*
KENDRICK P. PATTERSON*

DONALD J. FEATHERSTONE**
KAREN R. MARKOWICZ**
GRANT E. REED**
SUZANNE E. ZISKA**
BRIAN J. DEL BUONO**
VINCENT L. CAPUANO**
ANDREA J. KAMAGE**
NANCY J. DEGEN**

ROBERT H. BENSON*
OF COUNSEL

*BAR OTHER THAN D.C.
**REGISTERED PATENT AGENTS



December 21, 1999

WRITER'S DIRECT NUMBER:
(202) 789-5507

**Attn: Application Processing Division
Customer Correction Branch**

Assistant Commissioner for Patents
Washington, D.C. 20231

Re: U.S. Utility Patent Application
Appl. No. 09/390,634; Filed: September 7, 1999
For: **Method for Expanding Embryonic Stem Cells in Serum-Free
Culture (As Amended)**
Inventors: Price *et al.*
Our Ref: 0942.4190002/RWE/GER

Sir:

Transmitted herewith for appropriate action are the following documents:

1. Request for Corrected Official Filing Receipt;
2. A photocopy of the instant Official Filing Receipt with changes noted in red; and
3. One (1) return postcard.


It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Assistant Commissioner for Patents
December 21, 1999
Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036. A duplicate copy of this letter is enclosed.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

A handwritten signature in black ink, appearing to read "Grant E. Reed". The signature is fluid and cursive, with the first name "Grant" and last name "Reed" clearly distinguishable.

Grant E. Reed
Attorney for Applicants
Registration No. 41,264

Enclosures

1600
FILE COPY

SERIAL NUMBER 09/390,634	FILING DATE 09/07/99	CLASS 435	GROUP ART UNIT 1633	ATTORNEY DOCKET NO. 0942.4190002
APPLICANT	PAUL J. PRICE, GRAND ISLAND, NY; MINDY D. GOLDSBOROUGH, GAITHERSBURG, MD; MARY LYNN TILKINS, NIAGARA FALLS, NY.			
	APR 07 2000 TECH CENTER 1600/2900			
	CONTINUING DOMESTIC DATA*** VERIFIED THIS APPLN IS A DIV OF 08/781,772 01/10/97			
	371 (NAT'L STAGE) DATA*** VERIFIED			
FOREIGN APPLICATIONS*** VERIFIED				
IF REQUIRED, FOREIGN FILING LICENSE GRANTED 09/22/99				
Foreign Priority claimed 35 USC 119 (a-d) conditions met <input type="checkbox"/> yes <input type="checkbox"/> no Verified and Acknowledged <u>Examiner's Initials</u> <u>Initials</u>		STATE OR COUNTRY NY	SHEETS DRAWING 2	TOTAL CLAIMS 38
ADDRESS STERNE KESSLER GOLDSTEIN & FOX 1100 NEW YORK AVENUE N W SUITE 600 WASHINGTON DC 20005-3934		INDEPENDENT CLAIMS 17		
TITLE EMBRYONIC STEM CELL SERUM REPLACEMENT				
FILING FEE RECEIVED \$2,796	FEES: Authority has been given in Paper No. _____ to charge/credit DEPOSIT ACCOUNT NO. _____ for the following:		<input type="checkbox"/> All Fees <input type="checkbox"/> 1.16 Fees (Filing) <input type="checkbox"/> 1.17 Fees (Processing Ext. of time) <input type="checkbox"/> 1.18 Fees (Issue) <input type="checkbox"/> Other _____ <input type="checkbox"/> Credit	